Abciximab provides cost-effective survival advantage in high-volume interventional practice

• 31 October 2000
• journal article
• research article
• Published by Elsevier in American Heart Journal
• Vol. 140  (4) , 603-610
• https://doi.org/10.1067/mhj.2000.109647

Abstract

Keywords

• RANDOMIZED TRIAL
• CLINICAL TRIAL
• GLYCOPROTEIN
• PROPENSITY SCORE
• MYOCARDIAL INFARCT
• LEFT VENTRICULAR EJECTION FRACTION
• COST EFFECTIVENESS
• MORTALITY RATE